Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Endometrial Adenocarcinoma 1

Interventions

Paclitaxel 37Bevacizumab 34Carboplatin 30pembrolizumab 25Specimen Handling 21Magnetic Resonance Spectroscopy 19olaparib 18Cisplatin 15liposomal doxorubicin 13Taxes 13Immunoglobulin G 12Gemcitabine 12Disulfides 12Topotecan 9Nivolumab 9Cyclophosphamide 9Biopsy 9mirvetuximab soravtansine 7Doxorubicin 7fludarabine 6Radiation 6Fulvestrant 6niraparib 5durvalumab 5cediranib 5atezolizumab 5Platinum 5Oxaliplatin 5Fluorouracil 51,2-diaminocyclohexaneplatinum II citrate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
temsirolimus × Gynecologic × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡